Translational Cancer Medicine and Imaging
Dr Laura Kenny
What we do
We research novel positron emission tomography (PET) imaging methods for assessing cancer metabolism and response to treatment, as well as novel drugs for the treatment of cancer.
Why it is important
New drugs are important in improving the outcome for cancer patients and better imaging will help us define which patients may benefit from targeted therapies, detect resistance at an early time-point and enable patients to receive effective treatments.
How it can benefit patients
Through working as a clinician, we understand the problems that arise from current cancer treatments. The research we do directly involves patients, and we work closely with scientists to focus research that will have a meaningful impact for cancer patients.
Summary of current research
- [18F]GE226 – HERPET study: A new Affibody probe that will be studied in patients with breast cancer to determine if we can image the HER2 growth factor receptor non-invasively
- INC280 study: A commercial study of capmatinib in patients with advanced cancer
- IPET study: Irosustat window study, response assessment using FLT-PET
- POPPET study: Study of [18F]FLT-PET and [18F]FDG-PET in high grade ductal carcinoma in situ
- [18F]ICMT-11 as a marker of apoptosis in breast cancer patients undergoing neoadjuvant chemotherapy
Related Centres and Facilities
- AACR Young Investigator Award
- McElwain Prize
- ASCO Merit Award
For patient-related information please see:
When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page. If no studentships are currently advertised, please get in touch with the group lead with proposed project titles to discuss further.